MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$1,654,000
EPS
-$0.08
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
NaN NaN NaN 0
Research and development
684,000 538,000 608,000 496,000
General and administrative
1,006,000 877,000 827,000 960,000
Total operating expenses
1,690,000 1,415,000 1,435,000 1,456,000
Loss from operations
-1,690,000 -1,415,000 -1,435,000 -1,456,000
Interest income
36,000 50,000 37,000 34,000
Interest expense
NaN NaN NaN 0
Debt discount amortization
NaN NaN NaN 0
Total other income
36,000 50,000 37,000 34,000
Net loss
-1,654,000 -1,365,000 -1,398,000 -1,422,000
Basic EPS
-0.08 -0.067 -0.07 -0.08
Diluted EPS
-0.08 -0.067 -0.07 -0.08
Basic Average Shares
21,010,132 20,416,613 20,206,033 17,213,017
Diluted Average Shares
21,010,132 20,416,613 20,206,033 17,213,017
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$36,000 (800.00%↑ Y/Y)Net loss-$1,654,000 (-31.06%↓ Y/Y)Total other income$36,000 (800.00%↑ Y/Y)Loss from operations-$1,690,000 (-33.49%↓ Y/Y)Total operatingexpenses$1,690,000 (33.49%↑ Y/Y)General andadministrative$1,006,000 (30.14%↑ Y/Y)Research and development$684,000 (38.74%↑ Y/Y)

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)